InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$560.36

2026-10-16

Market Cap

$44.1B

Volume

0.7M

52-Wk High

$769.98

52-Wk Low

$500.61

Trailing PE

39.4

P/S

9.70

Gross Margin

62.4%

Net Margin

25.0%

ROE

72%

ROIC

41%

Piotroski

9/9

Altman Z

20.1

1-Yr Return

-12.1%

5-Yr Return

+99.1%

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

SectorHealthcareIndustryMedical - Diagnostics & ResearchExchangeNASDAQMarket Cap$44.1BEmployees11,000 (SEC-filed)CEOMichael EricksonIPO1991-06-21CountryUS

One IDEXX Drive, Westbrook, ME 04092 · Tel 207 556 0300 · idexx.com

INSIDERSTREET SCORE80 / 100Street mean $690.00 (3 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$19M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · IDXX -12.1% · S&P 500 +15.9% · spread -28.0pp

7 Years vs S&P 500 · IDXX +99.1% · S&P 500 +189.9% · spread -90.7pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE80of 100

Score Breakdown

Profitability	99/100
Growth	68/100
Momentum	85/100
Quality	94/100
Earnings Quality	69/100
Balance Sheet	70/100
Value	30/100
Risk (safety)	100/100
Overall	80.3/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
IQV	56
WAT	47
A	71
ILMN	58
NTRA	50
MTD	63
IDXX	80

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 80 in 26 Q2, latest 80 — +0 since. Fell in 0 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY80 / 100IS Score 80.3 / 100 · +0.0 from peak of 80

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 84 / 100 · Power +69 · 20 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 80 and price structure at 84 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 80.3	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 73 → 76 → 78 → 80	the direction matters more than the level
Technical vote share back above 50%	now 82%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,373 → now 1,296	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)1 buys2026-09-25

Insider Buys (180d)0none disclosed

ETF Funds (30d)1344 up / 1052 downnet +292 funds

Institutions Added (13F)-11managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,373 · latest 1,296 (-77 from peak).

Quarter	Holders	13F shares	Value	Reported own%	Guard
2026 Q2	1,296	74.5M	$38.5B	93.0%
2026 Q1	1,307	71.1M	$39.2B	88.8%
2025 Q4	1,373	80.3M	$47.7B	100.3%	ex-outlier 87.9%
2025 Q3	1,290	71.6M	$44.9B	89.4%
2025 Q2	1,227	74.0M	$39.0B	92.4%
2025 Q1	1,132	73.5M	$29.8B	91.8%
2024 Q4	1,113	71.5M	$28.8B	89.2%
2024 Q3	1,106	72.8M	$35.5B	90.9%
2024 Q2	1,097	74.2M	$35.4B	92.7%
2024 Q1	1,136	71.9M	$38.4B	89.8%
2023 Q4	1,139	72.1M	$39.7B	90.0%
2023 Q3	1,045	73.1M	$31.8B	91.3%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

Why 2025-12 reads 100.31%. Institutions cannot hold more of a company than exists. The reported 80.3M shares exceed the 80.1M outstanding, and a single filer accounts for the excess: VANGUARD GROUP INC reports 9,945,328 shares against 9,962,025 the prior quarter, a 1x jump, which alone would be 12.4% of the company. Excluding that filing, ownership is 87.9%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Kingsley Lawrence D	director	2026-09-04	EXERCISE	2,203	$0.25M	11,771
Kingsley Lawrence D	director	2026-09-04	SELL	2,203	$1.17M	9,568
Kingsley Lawrence D	director	2026-09-04	EXERCISE	2,203	$0.25M	0
Emerson Andrew	EVP, CFO and Treasurer	2026-08-20	EXERCISE	265	$0.05M	4,507
Emerson Andrew	EVP, CFO and Treasurer	2026-08-20	TAX W/H	86	—	4,421
Emerson Andrew	EVP, CFO and Treasurer	2026-08-20	EXERCISE	265	$0.05M	925
Hooley Joseph L	director	2026-07-30	A-Award	49	$0.03M	325
Fennell George	Executive Vice President	2026-06-01	EXERCISE	639	—	0

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	16	29,980	$19.4M	Counted
M — Exercises (paired A/D)	12	27,939	$3.8M	None — mechanics
F — Tax withholding	2	370	$0.2M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$19.4M16 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-09-04	Lawrence D Kingsley	2,203	$1.2M
2026-05-20	Margaret Anne Szostak	1,344	$0.7M
2026-03-03	Nimrata K Hunt	1,758	$1.1M
2026-02-26	Jonathan J Mazelsky	23,326	$15.3M
Trailing 12 mo	9 filings	58,929	$38M

Filed	Form	Reporting person	% of class	Shares
2026-04-30	SCHEDULE 13G	Vanguard Capital Management	7.51%	6.0M sh
2025-04-17	SCHEDULE 13G/A	BlackRock, Inc.	9.40%	7.6M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	BUY	$1,001 - $15,000	2026-09-25	2026-10-09
Ro Khanna	House	SELL	$15,001 - $50,000	2026-09-11	2026-10-09
Ro Khanna	House	SELL	$1,001 - $15,000	2026-09-04	2026-10-09
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2024-01-22	2024-02-14
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2024-01-22	2024-02-13
Thomas Hawley Tuberville	Senate	SELL	$1,001 - $15,000	2024-01-22	2024-02-13

House 12-Mo20 trades6 purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,307

13F Shares71M88.8% of shares out

New / Closed127 / 171positions, QoQ

Increased / Reduced431 / 511positions, QoQ

Put/Call (13F)1.25option positions

Free Float99.6%78M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Montrusco Bolton Investments Inc.	317,110	$166M
Assenagon Asset Management S.A.	256,362	$134M
Congress Asset Management Co	175,592	$92M
Seilern Investment Management Ltd	96,546	$50M
Vontobel Holding Ltd.	96,462	$50M
Mogy Joel R Investment Counsel Inc	85,486	$45M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.1%	$1.3B
VSMPX	0.1%	$1.3B
VTI	0.1%	$1.3B
VTSAX	0.1%	$1.3B
VOO	0.1%	$1.1B
VFINX	0.1%	$1.1B

13F Filers Holding IDXX — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session55.3%2026-10-15

20-Day Avg48.8%50-day 42.3%

TrendRising20d vs 50d

By Market CenterQ: 54% · N: 74% · B: 72%latest session

Weekly Notional ($B)

Where IDXX Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	0.7M	17 sh
Ubsa Ubs Ats	0.5M	22 sh
Mlix Instinct X	0.3M	24 sh
Sgmt Sigma X2	0.3M	14 sh
Ebxl Level Ats	0.2M	8 sh
Jpmx Jpm-X	0.2M	36 sh

Where a dollar of IDEXX Laboratories, Inc. revenue goes. All values FY2025 filings, live.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Region	Revenue	Share
UNITED STATES	$2.8B	61%
EMEA	$937M	21%
Asia Pacific	$356M	8%
Europe, the Middle East, and Africa, Other	$230M	5%
CANADA	$167M	4%
Latin America	$90M	2%

IDXX (live moat model)Peer median: IQV · WAT · A · ILMN · NTRA

Component scores from the live moat model. Peer median illustrative.

Moat score 71/100 — Wide; primary source Cost Advantage.

3.8 · Employees (SEC filings)

Officer	Title
Jonathan J. Mazelsky	Executive Chairman
Michael Erickson	President, Chief Executive Officer & Director
Michael J. Lane	Executive Vice President and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology
Martin Smith	Executive Vice President of Global Operations and R&D

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+6.3%

Next Report2026-11-02

Income Quality1.20OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Profit Margins (%)

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+18.8%	+4.7%	+8.7%	+6.5%	+10.4%
Gross profit	+20.3%	+6.1%	+9.3%	+8.6%	+11.8%
Operating income	+34.2%	-3.6%	+22.1%	+2.8%	+20.5%
Net income	+28.0%	-8.8%	+24.4%	+5.1%	+19.3%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	3.2	3.4	3.7	3.9	4.3
Cost of revenue	1.3	1.4	1.5	1.5	1.6
Gross profit	1.9	2.0	2.2	2.4	2.7
R&D expense	0.2	0.3	0.2	0.2	0.3
SG&A expense	0.8	0.9	0.9	1.0	1.0
Operating income	0.9	0.9	1.1	1.1	1.4
EBITDA	1.0	1.0	1.2	1.3	1.5
D&A	0.1	0.1	0.1	0.1	0.1
Pretax income	0.9	0.9	1.1	1.1	1.3
Income tax	0.2	0.2	0.2	0.2	0.3
Net income	0.7	0.7	0.8	0.9	1.1
Diluted EPS ($)	8.60	8.03	10.06	10.67	13.08
Diluted shares (M)	87	85	84	83	81

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Operating CF$1B

CapEx$0B

Free cash flow$1B

SBC$0B

Buybacks$1B

Net cash change$-0B

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	0.1	0.5	0.3	0.2
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	0.5	0.5	0.6	0.7
Total current assets	1.1	1.5	1.4	1.3
PP&E (net)	0.8	0.8	0.8	0.9
Goodwill + intangibles	0.5	0.5	0.5	0.5
Total assets	2.7	3.3	3.3	3.4
Accounts payable	0.1	0.1	0.1	0.1
Short-term debt	0.7	0.3	0.4	0.5
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	1.2	1.0	1.1	1.1
Long-term debt	0.7	0.6	0.4	0.5
Total liabilities	2.1	1.8	1.7	1.7
Shareholders' equity	0.6	1.5	1.6	1.6

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	0.7	0.8	0.9	1.1
D&A	0.1	0.1	0.1	0.1
Stock-based compensation	0.0	0.1	0.1	0.0
Working capital change	(0.3)	(0.1)	(0.1)	(0.2)
Operating cash flow	0.5	0.9	0.9	1.2
Capital expenditures	(0.1)	(0.1)	(0.1)	(0.1)
Investing cash flow	(0.2)	(0.1)	(0.2)	(0.1)
Buybacks	(0.8)	(0.1)	(0.8)	(1.2)
Dividends paid	0.0	0.0	0.0	0.0
Debt issuance / (repay)	0.4	(0.4)	(0.1)	(0.0)
Financing cash flow	(0.4)	(0.4)	(0.9)	(1.2)
Free cash flow	0.4	0.8	0.8	1.1

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	112.7%	104.6%	80.7%	57.7%	66.2%	72%
ROA	31.5%	26.2%	28.1%	27.1%	31.9%	33.1%
ROIC	48.8%	36.1%	41.6%	39.3%	43.5%	40.9%
Gross margin	58.8%	59.5%	59.8%	61.0%	61.8%	62.4%
Operating margin	29.0%	26.7%	30.0%	29.0%	31.6%	32.0%
Net margin	23.2%	20.2%	23.1%	22.8%	24.6%	25.0%
EBITDA margin	32.3%	30.1%	33.3%	32.7%	34.1%	35.5%
FCF margin	19.8%	11.7%	21.1%	20.5%	24.5%	—
VALUATION
P/E	76.15	50.35	55.13	38.43	51.52	39.4
P/B	82.21	56.17	31.38	21.39	34.00	27.8
P/S	17.64	10.15	12.73	8.76	12.68	9.70
P/FCF	89.18	86.75	60.28	42.76	51.81	35.3
EV/EBITDA	55.40	35.04	38.72	27.29	36.75	27.8
EV/Revenue	17.92	10.56	12.89	8.93	12.89	9.9
Earnings yield	1.3%	2.0%	1.8%	2.6%	1.9%	2.54%
FCF yield	1.1%	1.2%	1.7%	2.3%	1.9%	2.83%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.25	0.89	1.57	1.31	1.17	1.17
Quick ratio	0.90	0.59	1.17	0.95	0.84	0.87
Debt / equity	1.49	2.41	0.72	0.62	0.67	0.68
Debt / assets	42.3%	53.5%	32.7%	30.0%	32.1%	31.8%
Net debt / EBITDA	0.85	1.34	0.50	0.55	0.59	0.56
Interest coverage	31.28	22.58	26.52	36.60	33.97	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	1.36	1.30	1.22	1.19	1.30	1.32
Receivables turnover	8.45	7.94	7.67	7.45	7.40	6.1
DSO (days)	43	46	48	49	49	59
DPO (days)	26	30	27	27	25	28
Cash conversion cycle	83	101	113	114	109	115
GROWTH (YoY)
Revenue growth	18.8%	4.7%	8.7%	6.5%	10.4%	—
Net income growth	28.0%	-8.8%	24.4%	5.1%	19.3%	—
EPS growth	29.2%	-6.3%	24.3%	6.8%	22.1%	—
FCF growth	17.7%	-38.0%	96.1%	3.3%	32.0%	—
PER SHARE ($)
EPS (diluted, TTM)	8.65	8.10	10.07	10.76	13.13	14.23
Book value / share	8.01	7.26	17.69	19.33	19.90	20.13
Revenue / share	37.33	40.18	43.62	47.22	53.35	56.85
FCF / share	7.38	4.70	9.21	9.67	13.06	15.61
Cash / share	1.68	1.34	5.41	3.49	2.23	2.46
SHAREHOLDER RETURN & SCORES
Buyback yield	1.3%	2.4%	0.2%	2.5%	2.2%	2.77%
Altman Z-Score	23.83	13.68	20.09	16.77	24.13	20.1
Piotroski F-Score	8	4	6	8	7	9/9
Beneish M-Score	-2.26	-2.09	-2.48	-2.46	-2.42	-2.71

Model	Score	Zone	Note
Piotroski F-Score	9 / 9	Strong
Altman Z-Score	20.1	Safe (>2.99)	Safe
Income quality	1.20	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.71	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.80
Interest burden	0.97
Operating margin	32.1%
Asset turnover	1.34×
Financial leverage	2.21×
= ROE	74%

Growth Quality (live)	Value
Revenue stability	0.97
Earnings stability	0.87
Earnings persistence	0.94
Revenue CAGR 3y	9.0%
EPS CAGR 3y	14.4%
FCF CAGR 3y	27.5%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield2.77%

Dividend Yield0.00%none paid

Total Shareholder Return2.66%cash yield

SBC / Revenue-0.2%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
IQV	$43.9B	32.8	23%	5.9%	+8.2%	7/9	+29.8%
WAT	$42.9B	108.7	2%	-8.3%	+52.5%	5/9	+30.5%
A	$48.8B	34.0	21%	19.3%	+8.6%	7/9	+22.6%
ILMN	$39.6B	48.5	32%	17.9%	+4.9%	7/9	+173.7%
NTRA	$56.7B	-289.3	-13%	-8.9%	+37.8%	6/9	—
MTD	$32.5B	36.4	-736%	22.7%	+6.9%	8/9	—
DGX	$25.9B	24.6	14%	10.5%	+9.9%	8/9	—
LH	$25.8B	26.1	12%	8.0%	+6.4%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

23 Analysts

Str Sell (0)Sell (1)Hold (9)Buy (13)Str Buy (0)

Mean Target (qtr)$690.003 targets

Target vs. Price+23.1%last-quarter mean

Next Report2026-11-02street $3.72

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$4.72B	$4.73B / $4.71B	$14.76	$14.82 / $14.71	10
FY2027	$5.14B	$5.18B / $5.12B	$16.75	$17.09 / $16.34	11
FY2028	$5.62B	$5.75B / $5.47B	$19.04	$19.84 / $18.42	10

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$740.00	+32.1%	1
Last Quarter	$690.00	+23.1%	3
Last Year	$757.19	+35.1%	16
All Time	$654.61	+16.8%	31

Rolling mean of published targets vs. last close $560.36. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B

DCF

3/5

ROE

5/5

ROA

5/5

Debt/Eq

1/5

P/E

1/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

IDXX -12.1% vs S&P 500 +15.9% — spread -28.0pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$523.67	+36.69	+7.01%	Above
SMA 50	$535.25	+25.11	+4.69%	Above
SMA 200	$579.67	-19.31	-3.33%	Below
EMA 9	$533.00	+27.36	+5.13%	Above
EMA 21	$527.40	+32.96	+6.25%	Above
EMA 50	$533.27	+27.09	+5.08%	Above
EMA 200	$564.50	-4.14	-0.73%	Below

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +6920 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%78

Momentum 25%100

Volume 20%94

Volatility 10%100

Patterns 15%50

This Week82% bullishof 11 price-based votes

4 Weeks Ago0%+82 pts since

12 Weeks Ago9%+73 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$523.67

Price vs SMA 50$535.25

Price vs SMA 200$579.67

EMA 9/21 Cross533.0/527.4

SMA 50/200Death

ADX DirectionADX 16

Supertrend$519

Parabolic SAR$506

SMA Slope2.440

RSI66.0

Stochastic K/D89/77

StochRSI K/D100/90

Williams %R-9

CCI339

TSI vs Signal4.7

CMO32.0

ROC8.10%

OBV SignalAccum

Chaikin MF0.260

MFI65

Force Index3M

Elder Ray Bull38.81

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 77

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$543.43 / $551.58 / $555.97	S1 / S2	$539.04 / $530.89
Bollinger (20,2)	$499.82 – $547.51	Squeeze	Off
52-wk range	$500.61 – $769.98	Off 52-wk high	-27.2%
ATR (14)	$13.46 (2.4%)	Historical vol	24.8%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+2.7%Jan65%

+1.8%Feb50%

+0.6%Mar57%

+2.6%Apr75%

+0.7%May55%

+3.4%Jun65%

+5.6%Jul75%

+2.5%Aug55%

-1.4%Sep35%

-0.8%Oct55%

+1.6%Nov55%

+2.5%Dec70%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	IDXX	S&P 500
Weekly volatility (σ, 1y)	4.03%	1.83%
Best / worst week (1y)	+13.6% / -7.7%	—
Max drawdown (5y, monthly)	-51.3%	—
1-week VaR (95%)	-6.4%	—
Beta (5y)	1.54	1.00

IDXX EQUITY WEATHER (LIVE)PARTLY CLOUDY · +23

Trend+22

Momentum+61

Volume+66

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 163 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+23.0+40.0 vs industry

Trend+22.3+29.6 vs industry

Momentum+60.6+87.6 vs industry

Volume+65.8+65.8 vs industry

Reading	IDXX	Medical - Diagnostics & Research n=227	Healthcare n=5,272	All US symbols n=70,435
Overall	+23.0	-17.0	-24.0	-20.5
Trend	+22.3	-7.2	-25.6	-21.3
Momentum	+60.6	-27.0	-28.5	-15.8
Volume	+65.8	+0.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Jonathan J. Mazelsky President and Chief Exe	$14.6M	55% equity+incentive
Michael J. Lane Executive Vice President and	$4.0M	49% equity+incentive
Tina Hunt, PhD Executive Vice President, Glo	$3.9M	50% equity+incentive
Martin Smith, PhD Executive Vice President a	$3.9M	50% equity+incentive
Andrew Emerson Executive Vice President and	$3.0M	50% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	48
Social	53
Governance	64
Composite ESG	55

Composite ESG Trend

Filed	8-K contents	Items
2026-08-04	Earnings Release; Exhibits	2.02,9.01
2026-05-05	Earnings Release; Exhibits	2.02,9.01
2026-03-26	Officer/Director Change; Exhibits	5.02,9.01
2026-02-13	Departure/Election of Directors; Appointment of Officers	5.02
2026-02-02	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2026-01-13	Departure/Election of Directors; Appointment of Officers; Regulation F	5.02,7.01,9.01
2025-11-13	Entry into Material Definitive Agreement; Creation of Direct Financial	1.01,2.03,9.01
2025-11-03	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-29 to 2026-08-04
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	115 rows · 1987 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-05-12 to 2026-09-04
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	2 rows · 2025-04-17 to 2026-04-30
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc. (IDXX)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

IDEXX Laboratories, Inc. (IDXX)

Institutions holding — 12 quarters

IDEXX Laboratories, Inc. (IDXX)

Monthly Net Insider Flow (000 shares)

Signal Summary

IDEXX Laboratories, Inc. (IDXX)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding IDXX — quarterly

Institutional Put/Call — quarterly

IDEXX Laboratories, Inc. (IDXX)

Where IDXX Trades in the Dark

IDEXX Laboratories, Inc. (IDXX)

3.8 · Employees (SEC filings)

IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc. (IDXX)

Balance Sheet — Full

Cash Flow Statement — Full

IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc. (IDXX)

Street Price Target — Trajectory

Third-Party Composite Rating

IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc. (IDXX)

Family Scores (site weights)

IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc. (IDXX)

IDEXX Laboratories, Inc. (IDXX)